Astellas Pharma Inc. (4503) Stock Price

Astellas Pharma is a pharmaceutical company whose primary business activities are research and development, manufacturing, and sales of pharmaceutical products. The company operates through Astellas Pharma and 77 consolidated subsidiaries, along with 6 associates accounted for using the equity method, with its pharmaceutical business organized as a single reporting segment.

In research and development, Astellas Pharma Global Development Inc. (United States), Astellas Institute for Regenerative Medicine (United States), and Astellas Gene Therapies Inc. (United States) play key roles. These entities drive the development of innovative pharmaceutical products.

In manufacturing, Astellas Ireland Co., Ltd. (Ireland) and Astellas Pharma (China) Limited (China) handle product manufacturing. This enables the company to establish supply systems responsive to regional demand.

For sales, Astellas Pharma US, Inc. (United States), Astellas Pharma GmbH (Germany), and Beijing Astellas Pharma Limited (China) function as major sales hubs. These operations support the distribution of pharmaceutical products across global markets.

Astellas Pharma has formulated its medium-term management plan "Management Plan 2021" through fiscal year 2025 and is advancing its growth strategy. This plan aims to convert scientific progress into patient value and sets four strategic objectives. Through these efforts, the company seeks to remain at the forefront of healthcare innovation.

One strategic objective is to maximize patient outcomes. Astellas Pharma is focused on ensuring sustained access to its products and improving the results patients achieve. Additionally, concentrating resources on priority areas in research and development to enhance pipeline value is an important goal.

Furthermore, Astellas Pharma aims to advance its Rx+ business and support societal health by providing science-based healthcare solutions. The company is also strengthening its sustainability initiatives and promoting activities that benefit society and the environment.

The company has set three objectives to enhance organizational health. These efforts create an environment where employees collaborate effectively and generate innovation. Through these initiatives, Astellas Pharma pursues sustainable growth.

As performance targets, the company aims to achieve sales revenue of 1.2 trillion yen or more and a core operating profit margin of 30% or more by fiscal year 2025. This positions the company to become an enterprise with a market capitalization of 7 trillion yen or more. Astellas Pharma continues to advance its growth strategy to achieve these targets.